Title of Invention	"A PROCESS OF PREPARATION OF ANTIECZEMA AGENT FROM DRY MATURE SEEDS OF MYRISTICA FRAGRANS (NUTMEG)"
Abstract	Crushing air-dried mature seeds of Myristica fragrans to powder in an electric grinder. Mixing 100 gram of the said powder with 1.5 L of ethanol in a conical flask of 500 ml capacity. Keeping the flask containing the said powder mixing in ethanol at room temperature (25 ± 2°C) for a period of 10 days shaking it three times a day. Filtering the said powder mixed in ethanol through cotton (non-absorbable) after the said period of 10 days and collecting the filtrate in glass beakers. Keeping the said filtrate in the glass beakers for a period of one week for evaporation of ethanol when the pH comes to 5.5 and optical density 760 run to get antieczema agent in liquid form.

Title of Invention

"A PROCESS OF PREPARATION OF ANTIECZEMA AGENT FROM DRY MATURE SEEDS OF MYRISTICA FRAGRANS (NUTMEG)"

Abstract

Crushing air-dried mature seeds of Myristica fragrans to powder in an electric grinder. Mixing 100 gram of the said powder with 1.5 L of ethanol in a conical flask of 500 ml capacity. Keeping the flask containing the said powder mixing in ethanol at room temperature (25 ± 2°C) for a period of 10 days shaking it three times a day. Filtering the said powder mixed in ethanol through cotton (non-absorbable) after the said period of 10 days and collecting the filtrate in glass beakers. Keeping the said filtrate in the glass beakers for a period of one week for evaporation of ethanol when the pH comes to 5.5 and optical density 760 run to get antieczema agent in liquid form.

Full Text	Field of invention A process of preparation of antieczema agent from dry mature seeds of Myristica fragrans (Nutmeg). The principal aromatic constituent of the volatile oil of nutmeg, the dry ripe seeds of M. fragrans is myristicin or methoxysafrole. This yields 7-16% volatile oil which contains approximately 4-8% myristicin, the nutmeg contains approximately 1.3% myristicin. In addition to it the seed contains many other compounds also. The chemical name of myristicin is l-allyl-5-methoxy-3, 4 methylene-dioxybenzene; CAS No. 607-91-0; empirical formula: C11H12O3; molecular weight: 192- Many scientists have reported different properties of the extracts of dry seeds of M fragrans. Some scientists reported anaesthetic effect of methyl-euganol and other euganol derivatives of the volatile oil fraction of M. fragrans. In Nigeria and Indonesia, the essential oil of nutmeg is used in rheumatism, probably because the oil decreases the level of prostaglandins which are major mediators of the inflammatory action. This is also a known chemopreventor of chemically induced carcinogenesis. Its cytotoxic effect on cancer cells in vitro, also antibacterial activity against Staphylococcus aureus, and prevention of hypercholesterolemia and atherosclerosis in rabbits after supplementation with seed extract has been described. Chloroform extract of M. fragrans acts as analgesic, anti-inflammatory and antithrombotic,whereas crude nutmeg solution as well as ,its petroleum ether extract has been reported as antidiarrheal agent. Myristicin which is the major component of essential oil of nutmeg is reported to possess extraordinarily potent hepatoprotective activity in mice against lipopolysaccharide (LPS) plus d-galactosamine (D-GaIN) induced hepatotoxicity. Though it has several other properties its toxicological effects have not been proved as yet. ECZEMA Eczema or dermatitis is a reaction pattern and is the final common expression for a number of disorders such as atopic dermatitis, dyshydrotic eczema, nummular eczema, lichen simplex chronicus, asteotic eczema and seborrheic dermatitis. The eczema affecting hands is a very chronic disease and represents a large proportion of occupation-associated skin disease. It occurs as a reaction to contact allergens. Allergic dermatitis In allergic dermatitis the patient develops pruritic, edematous, erythematous papules and plaques and in some cases, vesicles usually between 24 to 72 hours after exposure to the antigen. Pruritis is very intense and so due to rubbing and scratching, cutaneous infections particularly with Staphylococcus aureus occurs in severe eczema marked by-weeping and crusting. Dermatitis of long standing is often dry and is characterized by thickened scaling skin which occurs after healing of the lesions. Irritant Contact Dermatitis This is non- allergic inflammatory reaction which occurs after exposure to an irritant, a toxic compound that causes a reaction in most individuals who come in contact with it. The response is determined by the type of irritant material, its quality and the type of exposure. Acute irritant contact dermatitis is variable and may be indistinguishable from allergic contact dermatitis. In chronic dermatitis dry ness and chapping occurs resulting into thickened scaling skin. Dyshydrotic dermatitis This is characterized by recurrent, severely pruritic, deep-seated vesicles that classically involves the lateral aspects of the fingers and thenar and hypothenar eminences. In some cases, toes are also involved. In chronic cases, more extensive involvement of the palms and soles occurs. Although the eruption develops acutely, it may become chronic with erythema slowly followed by crusts. The treatment of eczema is by removal of the offending agent which is very difficult to identify. The infection of the inflamed skin by Staphylococci or Streptococci is accordingly treated. Once the infection is over, treatment with high potency fluorinated topical glucocorticoids is enough to relieve symptoms though some patients might require its systemic therapy. In spite of all these treatments, the disease keeps on recurring and every time it recurs, it takes more severe form requiring higher doses of glucocorticoids. Description A process of preparation of antieczema agent from dry mature seeds of Myristicafragrans (Nutmeg) The objective of the present invention is to provide a process of preparation of antieczema agent from dry mature seeds of Mynstica fragrans. Process of extraction Accordingly the present invention provides a process of preparation of antieczema agent from dry mature seeds of Mynstica fragrans; comprising the steps of: A. Crushing air-dried mature seeds of Mynstica fragrans to powder in an electric grinder. B. Mixing 100 gram of the said powder with 1.5 L of ethanol in a conical flask of 500 ml capacity keeping the flask containing the said powder at room temperature (25±2°C) and shaking frequently for a period of 10 days. C. After ten days filtering the said powder mixed in ethanol through cotton (non-absorbable) and collecting the filtrate in glass beakers. D. Keeping for one week for the evaporation of ethanol when the pH comes to 5.5 and the optical density 760 nm. Thus obtained ethanol extract was applied to patients who were suffering from hand eczema and were resistant to glucocorticoid application. The drug was applied gently on the affected area thrice a day. The first application of the drug was soothing. After 5-6 applications the intensity of itching started reducing. After 3-4 days of application, the itching nearly stopped and thus the cycle of itching and oozing was broken. The inflammation started reducing with reduction in itching. This was followed by reduction in the size of eczematous vesicles. Gradually the smaller vesicles started resolving. The bigger the vesicle, the longer was the time in resolving them completely. No new vesicles erupted during the treatment. Gradually the affected hands became completely clean (free from any traces of the disease). The skin looked absolutely normal without any scaling. The patients were advised to apply the drug even after the vesicles had completely resolved, at least once in the morning and once in the evening just before going to bed. This stopped recurrence of the disease. The patients came for follow up to 6-12 months after which they stopped coming for check up probably, they had become free from the disease. Review of literature on the present invention reveals that no attempt has been made by any other inventor on the process of preparation of antieczema agent by the ethanol extract of Myristica fragrans. To the best of our knowledge no patent has been filed on this process outside or within India, hence no question of any amendment on the specification of our invention submitted by us. We claim 1 . A process of preparation of antieczema agent from dry mature seeds ofMyristica fragrant,; comprising the steps of: a. Crushing air-dried mature seeds of Myristica fragrans to powder in an electric grinder. b. Mixing 100 gram of the said powder with 1.5 L of ethanol in a conical flask of 500 ml capacity c. Keeping the flask containing the said powder mixed in ethanol at room temperature (25 ± 2°C) for a period of 10 days shaking it three times a day. d. Filtering the said powder mixed in ethanol through cotton (non-absorbable) after the said period of 10 days and collecting the filtrate in glass beakers. e. Keeping the said filtrate in the glass beakers for a period of one week for evaporation of ethanol when the pH comes to 5.5 and optical density 760 nm. 2. A process for the preparation of antieczema agent in liquid form at 5.5 pH and 756 nm optical density from ethanol extract of dry seeds ofMyristicafragrans substantially as herein described.

Full Text

Field of invention
A process of preparation of antieczema agent from dry mature seeds of Myristica fragrans (Nutmeg).
The principal aromatic constituent of the volatile oil of nutmeg, the dry ripe seeds of M. fragrans is myristicin or methoxysafrole. This yields 7-16% volatile oil which contains approximately 4-8% myristicin, the nutmeg contains approximately 1.3% myristicin. In addition to it the seed contains many other compounds also.
The chemical name of myristicin is l-allyl-5-methoxy-3, 4 methylene-dioxybenzene; CAS No. 607-91-0; empirical formula: C11H12O3; molecular weight: 192-
Many scientists have reported different properties of the extracts of dry seeds of M fragrans. Some scientists reported anaesthetic effect of methyl-euganol and other euganol derivatives of the volatile oil fraction of M. fragrans. In Nigeria and Indonesia, the essential oil of nutmeg is used in rheumatism, probably because the oil decreases the level of prostaglandins which are major mediators of the inflammatory action. This is also a known chemopreventor of chemically induced carcinogenesis. Its cytotoxic effect on cancer cells in vitro, also antibacterial activity against Staphylococcus aureus, and prevention of hypercholesterolemia and atherosclerosis in rabbits after supplementation with seed extract has been described. Chloroform extract of M. fragrans acts as analgesic, anti-inflammatory and antithrombotic,whereas crude nutmeg solution as well as ,its petroleum ether extract has been reported as antidiarrheal agent. Myristicin which is the major component of essential oil of nutmeg is reported to possess extraordinarily potent hepatoprotective activity in mice against lipopolysaccharide (LPS) plus d-galactosamine (D-GaIN) induced hepatotoxicity. Though it has several other properties its toxicological effects have not been proved as yet.
ECZEMA
Eczema or dermatitis is a reaction pattern and is the final common expression for a number of disorders such as atopic dermatitis, dyshydrotic eczema, nummular eczema, lichen simplex chronicus, asteotic eczema and seborrheic dermatitis. The eczema affecting hands is a very chronic disease and represents a large proportion of occupation-associated skin disease. It occurs as a reaction to contact allergens.
Allergic dermatitis
In allergic dermatitis the patient develops pruritic, edematous, erythematous papules and plaques and in some cases, vesicles usually between 24 to 72 hours after exposure to the antigen. Pruritis is very intense and so due to rubbing and scratching, cutaneous infections particularly with Staphylococcus aureus occurs in severe eczema marked by-weeping and crusting. Dermatitis of long standing is often dry and is characterized by thickened scaling skin which occurs after healing of the lesions.
Irritant Contact Dermatitis
This is non- allergic inflammatory reaction which occurs after exposure to an irritant, a toxic compound that causes a reaction in most individuals who come in contact with it. The response is determined by the type of irritant material, its quality and the type of exposure. Acute irritant contact dermatitis is variable and may be indistinguishable from allergic contact dermatitis. In chronic dermatitis dry ness and chapping occurs resulting into thickened scaling skin.
Dyshydrotic dermatitis
This is characterized by recurrent, severely pruritic, deep-seated vesicles that classically involves the lateral aspects of the fingers and thenar and hypothenar eminences. In some cases, toes are also involved. In chronic cases, more extensive involvement of the palms and soles occurs. Although the eruption develops acutely, it may become chronic with erythema slowly followed by crusts. The treatment of eczema is by removal of the offending agent which is very difficult to identify.
The infection of the inflamed skin by Staphylococci or Streptococci is accordingly treated. Once the infection is over, treatment with high potency fluorinated topical glucocorticoids is enough to relieve symptoms though some patients might require its systemic therapy.
In spite of all these treatments, the disease keeps on recurring and every time it recurs, it takes more severe form requiring higher doses of glucocorticoids.
Description
A process of preparation of antieczema agent from dry mature seeds of Myristicafragrans (Nutmeg)
The objective of the present invention is to provide a process of preparation of antieczema agent from dry mature seeds of Mynstica fragrans.
Process of extraction
Accordingly the present invention provides a process of preparation of antieczema agent from dry mature seeds of Mynstica fragrans; comprising the steps of:
A. Crushing air-dried mature seeds of Mynstica fragrans to powder in
an electric grinder.
B. Mixing 100 gram of the said powder with 1.5 L of ethanol in a
conical flask of 500 ml capacity keeping the flask containing the
said powder at room temperature (25±2°C) and shaking frequently
for a period of 10 days.
C. After ten days filtering the said powder mixed in ethanol through
cotton (non-absorbable) and collecting the filtrate in glass beakers.
D. Keeping for one week for the evaporation of ethanol when the pH
comes to 5.5 and the optical density 760 nm.
Thus obtained ethanol extract was applied to patients who were suffering from hand eczema and were resistant to glucocorticoid application. The drug was applied gently on the affected area thrice a day. The first application of the drug was soothing. After 5-6 applications the intensity of itching started reducing. After 3-4 days of application, the itching nearly stopped and thus the cycle of itching and oozing was broken. The inflammation started reducing with reduction in itching. This was followed by reduction in the size of eczematous vesicles. Gradually the smaller vesicles started resolving. The bigger the vesicle, the longer was the time in resolving them completely. No new vesicles erupted during the treatment. Gradually the affected hands became completely clean (free from any traces of the disease). The skin looked absolutely normal without any scaling. The patients were advised to apply the drug even after the vesicles had completely resolved, at least once in the morning and once in the evening just before going to bed. This stopped recurrence of the disease. The patients came for follow up to 6-12 months after which they stopped coming for check up probably, they had become free from the disease.
Review of literature on the present invention reveals that no attempt has been made by any other inventor on the process of preparation of antieczema agent by the ethanol extract of Myristica fragrans. To the best of our knowledge no patent has been filed on this process outside or within India, hence no question of any amendment on the specification of our invention submitted by us.

We claim
1 . A process of preparation of antieczema agent from dry mature seeds ofMyristica
fragrant,; comprising the steps of:
a. Crushing air-dried mature seeds of Myristica fragrans to powder in an electric
grinder.
b. Mixing 100 gram of the said powder with 1.5 L of ethanol in a conical flask of
500 ml capacity
c. Keeping the flask containing the said powder mixed in ethanol at room
temperature (25 ± 2°C) for a period of 10 days shaking it three times a day.
d. Filtering the said powder mixed in ethanol through cotton (non-absorbable) after
the said period of 10 days and collecting the filtrate in glass beakers.
e. Keeping the said filtrate in the glass beakers for a period of one week for
evaporation of ethanol when the pH comes to 5.5 and optical density 760 nm.
2. A process for the preparation of antieczema agent in liquid form at 5.5 pH and 756 nm optical density from ethanol extract of dry seeds ofMyristicafragrans substantially as herein described.

Documents:

1442-del-2003-abstract.pdf

1442-del-2003-claims.pdf

1442-del-2003-correspondence-others.pdf

1442-del-2003-correspondence-po.pdf

1442-del-2003-description (complete).pdf

1442-del-2003-form-1.pdf

1442-del-2003-form-13.pdf

1442-del-2003-form-19.pdf

1442-del-2003-form-2.pdf

« Previous Patent

Next Patent »

Patent Number

235990

Indian Patent Application Number

1442/DEL/2003

PG Journal Number

38/2009

Publication Date

18-Sep-2009

Grant Date

10-Sep-2009

Date of Filing

21-Nov-2003

Name of Patentee

SING UDAI PRATAP

Applicant Address

DEPARTMENT OF MYCOLOGY AND PLANT PATHOLOGY INSTITUE OF AGRICULTURAL SCIENCES, BANARAS HINDU UNIVERSITY VARANASI 221005 INDIA

Inventors:

#	Inventor's Name	Inventor's Address
1	SING UDAI PRATAP	DEPARTMENT OF MYCOLOGY AND PLANT PATHOLOGY INSTITUE OF AGRICULTURAL SCIENCES, BANARAS HINDU UNIVERSITY VARANASI 221005 INDIA.
2	SINGH MANDAVI	DEPARTMENT OF MYCOLOGY AND PLANT PATHOLOGY INSTITUE OF AGRICULTURAL SCIENCES, BANARAS HINDU UNIVERSITY VARANASI 221005 INDIA.
3	SINGH RAVI VIKRAM	136/D, SHRI KRISHNA PURI, PATNA, BIHAR, INDIA.

PCT International Classification Number

A61K 35/78

PCT International Application Number

N/A

PCT International Filing date

PCT Conventions:

#	PCT Application Number	Date of Convention	Priority Country
1			NA